Literature DB >> 10471636

Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium.

G Khoukaz1, N J Gross.   

Abstract

Administration of beta-adrenergic agonist bronchodilators to patients with airways obstruction commonly results in transient decreases in Pa(O(2)) levels despite bronchodilation, an effect that has been attributed to these drugs' pulmonary vasodilator action. We compared the acute effects on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructive pulmonary disease (COPD). Each agent was given in recommended dosage on separate days in a double-blind, crossover format, and the patients' arterial blood gases (ABGs) were measured at baseline and at intervals to 120 min. Small but statistically significant declines in Pa(O(2)), the primary outcome variable, were found after administration of both salmeterol and albuterol. The decline in PaO2 after salmeterol was of lesser magnitude but was more prolonged than that after albuterol, the greatest mean change being -2.74 +/- 0.89 mm Hg (mean +/- SEM) at 30 min after salmeterol, and -3.45 +/- 0.92 mm Hg at 20 min after albuterol. Following ipratropium, the corresponding change was -1.32 +/- 0.85 mm Hg at 20 min. These declines, which were almost entirely attributable to increases in the alveolar-arterial difference in oxygen tension Delta(A-a)DO2 tended to be more marked in subjects with higher baseline PaO2 values. No subject experienced a decline in PaO2 to levels below 59 mm Hg. There were no significant differences among the three drugs studied. We conclude that despite small decreases in PaO2 after each of the three drugs, the declines were small transient, and of doubtful clinical significance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471636     DOI: 10.1164/ajrccm.160.3.9812117

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

Review 1.  COPD exacerbations.5: management.

Authors:  R Rodríguez-Roisin
Journal:  Thorax       Date:  2006-06       Impact factor: 9.139

Review 2.  Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.

Authors:  B Jarvis; A Markham
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

4.  Effects of rac-albuterol on arterial blood gases in patients with stable hypercapnic chronic obstructive pulmonary disease.

Authors:  Christopher I Whale; Milind P Sovani; Kevin Mortimer; Janet Oborne; Sue Cooper; Timothy W Harrison; Anne E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

Review 5.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

6.  Effect of salmeterol/fluticasone combination on the dynamic changes of lung mechanics in mechanically ventilated COPD patients: a prospective pilot study.

Authors:  Wei-Chih Chen; Hung-Hsing Chen; Chi-Huei Chiang; Yu-Chin Lee; Kuang-Yao Yang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-01-27

7.  Effect of Tiotropium Soft Mist Inhalers on Dynamic Changes in Lung Mechanics of Patients with Chronic Obstructive Pulmonary Disease Receiving Mechanical Ventilation: A Prospective Pilot Study.

Authors:  Pin-Kuei Fu; Yu-Feng Wei; Chau-Chyun Sheu; Chen-Yu Wang; Chi-Kuei Hsu; Chia-Min Chen; Wei-Chih Chen; Kuang-Yao Yang
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.